Channel: Cancer Research UK

Category: Science & Technology

Tags: antibodyuniversity college londoncd25immunitycd25 activationcancer research ukt cellscancer immunotherapyimmunotherapyimmune systemrocheantibodiesimmunologycancer and the immune system

Description: The shared CD25 activation mechanism on regulatory and effector T-cells has been a big challenge when designing immunotherapy drugs. Cancer Research UK scientists from University College London in collaboration with Roche, have developed a new antibody that can target CD25 specifically on regulatory T-cells while leaving effector T-cells intact. Watch this antibody in action in this short animation. Read Prof Quezada's latest Nature paper on this area of research: nature.com/articles/s43018-020-00133-0 For more information about our latest science and innovation news on: Twitter: twitter.com/CRUKresearch LinkedIn: linkedin.com/showcase/cancer-research-uk-translation-&-commercialisation-